Loading
companiesCompany
Debiopharm
Debiopharm is the private Swiss developer of the WEE1 inhibitor zedoresertib (Debio 0123) and of dual-payload ADC research.
Overview
Zedoresertib is a brain-penetrant, selective WEE1 inhibitor in phase 1/2 as monotherapy and with carboplatin (platinum-resistant ovarian) or with the PKMYT1 inhibitor lunresertib in CCNE1/FBXW7/PPP2R1A-altered tumours (first data AACR 2026). Debiopharm also presented dual-payload ADC and AI-biomarker work at AACR 2026.
Headquarters
Lausanne, CH
Scorecard
All companies#490of 1244 companies, score 4
- modalities +2
- registry trials +5
- failures -3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 6 registry studies. Formula on the scorecards page.
Type
Website
NegativeOral IAP antagonist (SMAC mimetic) radiosensitiser
Xevinapant was a tablet meant to make head and neck cancer cells easier to kill with chemoradiation by removing the proteins that stop them dying. A promising mid-stage trial was followed by a phase 3 that was stopped in 2024 because it was not working.
Similar pages
- CompanyZentalis Pharmaceuticals
Shares WEE1, Ovarian cancer.
- CompanyAcrivon Therapeutics
Shares WEE1, Ovarian cancer.
- TreatmentAzenosertib
Shares WEE1, Ovarian cancer.
- TechnologyATR and CHK1 inhibitors
- CompanySutro Biopharma
Shares Dual-payload ADC, Ovarian cancer.
- IdeaTurn chromosomal chaos into a weakness with KIF18A inhibitors
- PersonAlan D. D'Andrea
- PersonAlan Ashworth
cancers
fronts
technologies
targets
drugs
NegativeOral IAP antagonist (SMAC mimetic) radiosensitiser
trials
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaA Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)TrilynX